Jonathan M. Rothberg, Ph.D. is the founder of our predecessor entity and has served on our board of directors since the closing of the business combination in June 2021. He was appointed Chairman of the Board in June 2021 and served in this role until May 2024 when Mr. Kummeth was appointed as Chairman but continues to serve as a member of the Board. Dr. Rothberg also served as our Interim Chief Executive Officer from February 2022 to October 2022. Dr. Rothberg had served as the Executive Chairman of our predecessor entity since December 2015 and as the Chief Executive Officer from December 2015 to November 2020. Dr. Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder of each of its companies: Quantum-Si, AI Therapeutics, Inc. (formerly LAM Therapeutics, Inc.), Butterfly Network, Inc., Detect, Inc. (formerly Homodeus Inc.), Hyperfine, Inc., identifeye Health Inc. (formerly Tesseract Health, Inc.), Liminal Sciences, Inc. (formerly EpilepsyCo Inc.), and Protein Evolution, Inc.
Additionally, Dr. Rothberg has served as an Adjunct Professor of Research of Genetics at Yale School of Medicine since July 2015. Dr. Rothberg previously founded and served as Chairman, Chief Executive Officer, and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007 to 2010, and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Inc. from 2004 to 2009. From 1999 to 2007, Dr. Rothberg co-founded and served as Chairman of ClarifI, Inc., and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation, a biotechnology company. Prior to 454 Life Sciences Corporation, Dr. Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation, a biopharmaceutical development company, from 1993 to 2004. From March 2014 to April 2020, Dr. Rothberg served as Interim Chief Executive Officer of Butterfly Network, Inc. and currently serves on the board of directors of Butterfly Network, Inc. He also served as the Chief Executive Officer of the legacy Company of Hyperfine, Inc., a health technology company, from 2014 to 2021 and currently serves on the board of directors of Hyperfine, Inc.
Dr. Rothberg received his Ph.D., M. Phil. and M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University. Dr. Rothberg’s qualifications to serve on our board of directors include his significant scientific, executive and board leadership experience in the technology industry, as well as his knowledge of our business as our predecessor entity’s founder.
